J
Jonathan A. Ledermann
Researcher at University College London
Publications - 332
Citations - 28241
Jonathan A. Ledermann is an academic researcher from University College London. The author has contributed to research in topics: Ovarian cancer & Olaparib. The author has an hindex of 65, co-authored 300 publications receiving 21862 citations. Previous affiliations of Jonathan A. Ledermann include University College London Hospitals NHS Foundation Trust & University College Hospital.
Papers
More filters
Journal ArticleDOI
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
Charlie Gourley,Judith Balmaña,Jonathan A. Ledermann,Violeta Serra,Rebecca Dent,Sibylle Loibl,Eric Pujade-Lauraine,Simon J. Boulton +7 more
TL;DR: The most recent evidence for the clinical effect of PARP inhibition in breast and ovarian cancer is reviewed and expansion into the first-line setting and into other tumor types is explored.
Journal ArticleDOI
Corrections to "Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"
Jonathan A. Ledermann,Fharat A. Raja,Christina Fotopoulou,Antonio González-Martín,Nicoletta Colombo,Cristiana Sessa +5 more
Journal ArticleDOI
Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study
M.L. Harrison,Paul Hoskins,A. du Bois,Michael A. Quinn,G. J. S. Rustin,Jonathan A. Ledermann,S. Baron-Hay,Michael Friedlander +7 more
TL;DR: A multi-modality treatment approach including surgery, chemotherapy with the addition of radiotherapy either sequentially or concurrently is advocated for patients with SCCOHT.
Journal ArticleDOI
Herpes Simplex Virus Infection of Dendritic Cells: Balance among Activation, Inhibition, and Immunity
Gabriele Pollara,Katharina Speidel,Laila Samady,Mansi Rajpopat,Yvonne McGrath,Jonathan A. Ledermann,Robert S. Coffin,David R. Katz,Benjamin M. Chain +8 more
TL;DR: Data support a pathogenetic model of HSV infection, in which initial delay in the generation of immune responses to HSV at peripheral sites is mediated by disruption of DC function but is overcome by bystander DC maturation and cross-presentation ofHSV antigens.
Journal ArticleDOI
Safety and dose modification for patients receiving niraparib
Jonathan S. Berek,Ursula A. Matulonis,U. Peen,Prafull Ghatage,Sven Mahner,Sven Mahner,Andrés Redondo,A. Lesoin,Nicoletta Colombo,Ignace Vergote,O. Rosengarten,Jonathan A. Ledermann,Mario Javier Pineda,Susan Ellard,Jalid Sehouli,Antonio González-Martín,Dominique Berton-Rigaud,Radoslaw Madry,Alexander Reinthaller,Sebastien Hazard,W. Guo,Mansoor Raza Mirza +21 more
TL;DR: The analysis presented suggests that patients with baseline body weight of <77 kg or baseline platelets of<150 000/µl may benefit from a starting dose of 200 mg/day, which was the most commonly administered dose in the ENGOT-OV16/NOVA trial.